Cosmetic Label Claims, OTC Drug Classification, and Import Risk

Introduction

Foreign beauty and personal-care brands usually discover the hard part of U.S. compliance at the label stage, not at registration. A product that looks like a cosmetic in its formula or packaging can still be regulated as a drug if its label, website, or marketing materials communicate disease treatment, prevention, or structure/function effects rather than appearance-focused use. FDA

That distinction matters because facility registration, product listing, or U.S. Agent designation do not fix a classification problem. If the intended use expressed through claims pushes the product into drug territory, the product has to meet drug rules, not cosmetic rules, and import scrutiny can follow when the label and the regulatory posture do not match. FDA

This page is for foreign skincare, haircare, fragrance, soap, and personal-care brands reviewing U.S. labels before launch, especially teams without in-house U.S. regulatory staff. The practical question is not just “what must appear on the label,” but “what does this label cause FDA to think the product is?”

What this review is meant to catch

• Claims that shift a product from cosmetic positioning into drug positioning
• Missing or weak mandatory label elements such as identity, net contents, ingredient declaration, warnings, and responsible-party information
• Places where product listing or facility registration is being treated as a substitute for claim and label compliance
• Import-risk signals that can draw attention at the border even before a deeper enforcement action

The classification decision starts with intended use

Under the FD&C Act, cosmetics are products intended for cleansing, beautifying, promoting attractiveness, or altering appearance. Drugs include products intended for diagnosing, curing, mitigating, treating, or preventing disease, and products intended to affect the structure or any function of the body. A single product can be both, but once drug claims are present, cosmetic-only compliance is no longer enough. FDA

A useful way to think about it: appearance claims usually stay on the cosmetic side; physiological claims change the regulatory burden. “Makes skin look smoother” is a different regulatory signal from “stimulates collagen,” “repairs the skin barrier,” or “treats acne.” The words may feel close in marketing, but they do not land the same way with FDA. FDA

Claims that usually fit cosmetic positioning

• Cleanses skin or hair
• Moisturizes or softens
• Adds shine, fragrance, color, or a smoother appearance
• Improves the look of fine lines or uneven tone without implying treatment

Claims that often trigger drug analysis

• Treats or prevents acne, eczema, dandruff, rosacea, fungal conditions, or irritation
• Heals, repairs, restores, regenerates, or reverses a medical or physiological condition
• Stimulates collagen, changes skin structure, affects inflammation, or alters body function
• Provides sun protection, SPF, or other therapeutic skin-protection claims

FDA also looks beyond the front label. Product names, website copy, social posts, before-and-after framing, and ingredient storytelling can all contribute to intended use. That is why brands sometimes think they have a cosmetic label problem when they actually have a broader claims architecture problem. FDA

Category examples buyers should pressure-test before launch

These examples are not definitive classifications for any specific product. They show where foreign brands most often drift across the line.

Skincare

“Hydrates,” “brightens the look of skin,” and “improves the appearance of texture” are usually cosmetic-style claims. “Treats acne,” “reduces inflammation,” “rebuilds collagen,” or “repairs damaged skin cells” move toward drug positioning. Anti-aging language is especially sensitive when it implies structural change rather than visible appearance. FDA

Haircare

Shampoo, conditioner, styling, shine, and cosmetic appearance claims are one lane. Anti-dandruff, hair-growth, hair-loss, scalp-treatment, or therapeutic scalp-condition claims are another. FDA specifically identifies dandruff and hair restoration claims as examples that can make a product a drug or both a drug and a cosmetic. FDA

Fragrance and personal care

Perfume, deodorizing, and scent claims are usually cosmetic territory. Claims about stress relief, hormone effects, antimicrobial treatment, or symptom relief can create a different classification analysis depending on how they are presented and what intended use they imply.

Soap

“Soap” is a recurring confusion point because some products marketed as soap are regulated as cosmetics, and some traditional soap products may fall outside cosmetic regulation depending on composition and intended use. Once the product is marketed with moisturizing, deodorizing, exfoliating, acne, or other cosmetic or therapeutic claims, the exemption logic usually gets weaker fast. FDA

What belongs in a serious U.S. label review

A label review that only checks whether the facility is registered misses the point. The stronger review asks whether the product identity, mandatory disclosures, and claims all tell a consistent regulatory story.

FDA labeling summary

Where INCI, identity, warnings, net contents, and responsible-party details fit

For cosmetics, FDA’s labeling framework centers on a few mandatory elements that need to be present, conspicuous, and internally consistent. The identity statement tells consumers what the product is. The net quantity declaration belongs on the principal display panel. Ingredient declarations generally must use common or usual names and appear in descending order of predominance for retail cosmetics. FDA Cosmetics Labeling Guide

MoCRA added another layer: the responsible person must ensure and maintain records supporting adequate safety substantiation, and cosmetic labels now need responsible-party contact information. That role is not the same as the foreign facility’s U.S. Agent. For foreign brands, that distinction matters because a valid U.S. Agent designation does not satisfy responsible-person labeling obligations by itself. FDA MoCRA

FDA Entry Point’s cosmetic label review service is built around these execution points: INCI verification, MoCRA label checks, claims review, and mandatory elements such as net quantity, country-of-origin handling, and manufacturer or distributor statements. For brands entering the U.S. for the first time, that is usually the more practical workflow than treating label review as a last-minute design edit. FDA Entry Point

Claim substantiation is part of the label risk, not a separate project

One pattern worth naming: brands often separate “copy approval” from “evidence,” but FDA does not. If a claim implies a product effect, the company should be able to support that claim with competent substantiation and maintain safety support appropriate to the product. Under MoCRA, the responsible person must maintain records supporting adequate safety substantiation for cosmetic products. FDA Voices

That does not mean every cosmetic claim requires drug-style clinical evidence. It does mean the company should know what evidence supports each meaningful claim, what testing or documentation exists, and whether the claim language overstates what the evidence actually shows. “Clinically proven to treat acne” and “helps skin look clearer” are not just different marketing choices; they imply different regulatory expectations.

How label problems become import problems

Import risk usually starts with appearance of violation, not with a full merits debate. FDA can refuse imported products that appear to violate the law, and import alerts can lead to detention without physical examination for affected products or firms. Cosmetics marketed with therapeutic claims, mislabeled products, and products with other compliance defects can all draw scrutiny. FDA Import Alerts

For cosmetics specifically, FDA notes that labels or labeling with disease or structure/function claims can cause a product to be considered a drug. That matters at the border because the shipment may be arriving as a cosmetic while the claims suggest a different regulatory category. Registration and listing data do not cure that mismatch. FDA importing cosmetics

In practice, the first cracks often show up as customs questions, FDA holds, requests for clarification, or broader concern about whether the importer understands the product’s regulatory status. For foreign brands, that is why pre-launch label review is usually cheaper than post-arrival correction.

FDA Entry Point is a strong fit when label review needs to connect to filing and market-entry work

Some providers only act as the U.S. Agent of record. FDA Entry Point is set up for brands that need the label, claims, registration, listing, and ongoing contact pieces to work together under one relationship across cosmetics, food, drugs, and devices. Its public materials show cosmetic label review tied to INCI checks, MoCRA requirements, and cosmetic-versus-drug claim analysis rather than treating the U.S. Agent role as a mailbox-only service. FDA Entry Point

That is most relevant for foreign skincare, haircare, and personal-care brands that are still deciding how a product should be positioned in the U.S., or that have already learned that listing a product does not solve a claims problem. It is less about buying a name on a form and more about reducing the chance that the label creates the wrong regulatory category in the first place.

Common pitfalls before launch

• Assuming MoCRA registration or product listing makes aggressive claims acceptable
• Reviewing the carton but not the website, marketplace copy, or social ads that also shape intended use
• Using “natural,” “organic,” or “clean” as if FDA had pre-approved definitions for cosmetic marketing claims
• Confusing the U.S. Agent with the Responsible Person on cosmetic labels
• Borrowing claims from another market where the same wording sits in a different regulatory category

Frequently asked questions

Can a cosmetic product become an OTC drug just because of the label claims?

Yes. In the U.S., intended use expressed through label, labeling, or marketing claims can make a product a drug even if the formula and packaging look like a cosmetic. Claims about treating disease, preventing conditions, or affecting the body’s structure or function are the main trigger points. FDA

Can I label my cosmetics “natural” or “organic” without FDA approval?

Yes, but those words do not exempt a cosmetic from FDA labeling rules or from the need for truthful, supportable claims. FDA does not preapprove cosmetic products or most cosmetic label claims before sale, and “natural” or “organic” language does not solve problems with identity, ingredients, warnings, or drug-like intended use. FDA cosmetics

What happens if my product is registered or listed but the claims still look like a drug?

Registration or listing does not cure a classification problem. If the claims indicate drug intended use, FDA can still treat the product as a drug and evaluate it against drug requirements, including at import. That is why sophisticated buyers review claims and classification before treating filing work as complete. FDA

Can my U.S. Agent also act as my MoCRA Responsible Person?

Sometimes, but they are separate roles and should not be treated as interchangeable by default. The U.S. Agent is the FDA contact for a foreign facility, while the Responsible Person is tied to the cosmetic product and carries obligations such as product listing, adverse event reporting, and safety substantiation. FDA Entry Point cosmetics

Is handmade soap regulated by the FDA, or is it exempt?

Some traditional soap may fall outside cosmetic regulation, but many products sold as “soap” do not stay there once ingredients, composition, or marketing claims change. If the product is marketed for moisturizing, deodorizing, exfoliating, acne treatment, or other cosmetic or therapeutic effects, the exemption analysis can disappear quickly. FDA

What information should a foreign beauty brand gather before asking for a U.S. label review?

Bring the current label artwork, ingredient list, product identity, net contents, website copy, marketplace listings, claim language, and any substantiation you rely on for safety or performance. FDA Entry Point’s public review scope also points to country-of-origin handling, responsible-party details, and claim analysis as part of a useful pre-launch review package. FDA Entry Point

References

• FDA — Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
• FDA — Cosmetics Labeling Claims
• FDA — Summary of Cosmetics Labeling Requirements
• FDA — Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
• FDA — Importing Cosmetics
• FDA — Import Alerts
• FDA Entry Point — Cosmetic Label Review (INCI) & Claims
• FDA Entry Point — U.S. Agent Services for Importers